Biotech China 2014
Great Debates and Updates in Hematologic Malignancies
Westin New York Times Square
New York, New York
Great Debates and Updates in Hematologic Malignancies

Schedule of Presentations:

Friday, April 30, 2010
08:00:00 Introduction
08:10:00 Acute Leukemia Session
08:15:00 Debate: Is chemotherapy still useful for APL in the era of ATRA and arsenic trioxide? Gary Schiller, Harold P. Erba
08:35:00 Debate: What is the most appropriate and effective therapy for elderly AML patients? Harold P. Erba, Gary Schiller
09:00:00 Emerging novel and promising therapeutic agents for AML Stephen Nimer
09:25:00 Coffee break
09:45:00 Lymphoma Session I
09:50:00 Debate: Should the results of interim PET scans change the planned management of advanced hodgkins lymphoma or diffuse large Craig Moskowitz, Morton Coleman
10:10:00 Debate: Should surveillance CT scans be performed on DLBC lymphoma patients who achieve a CR from frontline therapy? Peter Martin, Andrew D. Zelenetz, MD, PhD
10:35:00 Debate: What is the most appropriate second line therapy for advanced follicular lymphoma patients who relapse following frontline R-CHOP? John P. Leonard, Andrew D. Zelenetz, MD, PhD, Craig Moskowitz
11:05:00 What is the most appropriate management for stage I follicular lymphoma in a young patient - deciding when and with what to initiate therapy? John P. Leonard
11:35:00 Lunch
12:40:00 Myeloma Session I
12:40:00 Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed multiple myeloma patients? S. Vincent Rajkumar, Sagar Lonial
13:05:00 Debate: What is the most appropriate frontline regimen for transplant ineligible myeloma patients? S. Vincent Rajkumar, Sagar Lonial, Steven P. Treon
13:30:00 Debate: How should bisphosphonates be utilized in multiple myeloma patients responding to frontline therapy? Robert Z. Orlowski
13:55:00 Debate: For newly diagnosed SCTeligible myeloma patients the most appropriate induction therapy is: Shaji Kumar, Sagar Lonial
14:35:00 Coffee break
14:55:00 Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML? Hagop M. Kantarjian, Gail J Roboz
14:55:00 CML Session
15:25:00 Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML? Stephen Nimer, Jorges Cortes
15:55:00 Evolving and promising therapeutic strategies for post-TKI failure in CML Hagop M. Kantarjian
16:20:00 Adjourn
Saturday, May 1, 2010
08:05:00 CLL Session
08:05:00 Debate: FCR is the best frontline therapy for CLL patient ≥65 years of age Asher A. Chanan-Khan, Susan O’Brien
08:30:00 Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL? Asher A. Chanan-Khan, Susan O’Brien
08:55:00 Myeloproliferative neoplasm session Richard T. Silver
09:10:00 How I deal with the difficult questions in the management of Essential Thrombocythemia Ruben A Mesa
09:25:00 What is the role of allogeneic transplantation in myeloproliferative neoplasms Ruben A Mesa, Jorges Cortes
09:50:00 Coffee break
10:10:00 How I manage multiple myeloma patients who present with significant pre-existing illnesses or serious complications of the myeloma: Rafael Fonseca, Shaji Kumar, S. Vincent Rajkumar
10:10:00 Myeloma Session II
10:50:00 Debate: For newly diagnosed multiple myeloma patients who relapse from a ≥VGPR response more than 12 months following frontline therapy, what is the best salvage strategy? Rafael Fonseca, Robert Z. Orlowski
11:15:00 The next great therapeutic challenge in multiple myeloma: Designing novel agents and combinations to overcome myeloma
11:20:00 cell resistance to proteasome and immunomodulatory agents
11:40:00 Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia? Steven P. Treon, Shaji Kumar
13:10:00 Lymphoma Session II
13:10:00 Emerging and promising novel agents for B-cell and T-cell lymphomas Owen A. O’Connor
13:40:00 Debate: Should treatment for limited stage non-bulky hodgkins lymphoma include radiation therapy? Morton Coleman, Peter Martin
14:05:00 Coffee break
14:25:00 Debate: What is the best therapy for MDS patients with deletion 5q? Guillermo Garcia-Manero, Gail J Roboz
14:25:00 MDS Session Richard T. Silver
14:50:00 Debate: What is the best frontline therapy for intermediate-2 and high risk MDS? Gail J Roboz, Jorges Cortes
15:15:00 Novel and evolving therapeutic strategies for MDS Guillermo Garcia-Manero
15:40:00 Summary
15:50:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.